Your browser doesn't support javascript.
Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic.
Stecca, Carlos E; Jiang, Di Maria; Veitch, Zachary; Hotte, Sebastian J; Alimohamed, Nimira; Wood, Lori; Sridhar, Srikala S.
  • Stecca CE; Division of Medical Oncology and Hematology, University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Jiang DM; Division of Medical Oncology and Hematology, University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Veitch Z; Division of Medical Oncology and Hematology, Saint Michael's Hospital, Toronto, ON, Canada.
  • Hotte SJ; Division of Medical Oncology and Hematology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
  • Alimohamed N; Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
  • Wood L; Division of Medical Oncology, Nova Scotia Health, Dalhousie University, Halifax, NS, Canada.
  • Sridhar SS; Division of Medical Oncology and Hematology, University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: srikala.sridhar@uhn.ca.
Clin Genitourin Cancer ; 21(2): 273-277, 2023 04.
Article in English | MEDLINE | ID: covidwho-2245445
ABSTRACT

BACKGROUND:

In metastatic hormone sensitive prostate cancer (mHSPC), treatment intensification with either docetaxel or an androgen-receptor-axis targeted therapy (ARAT), added to androgen deprivation therapy (ADT) is the new standard of care. To better understand patterns of treatment intensification in Canada and specifically how it has been influenced by the COVID-19 pandemic, we conducted a national survey of genitourinary medical oncologists from across Canada.

METHODS:

Using SurveyMonkey, we conducted an online survey of 119 medical oncologists in Canada from January 15 to January 27, 2021. The survey consisted of 16 questions, including demographics, and asked specifically about their approach to managing mHSPC before and during the pandemic.

RESULTS:

Overall there were 50/119 (42%) respondents. Most were male (65%), from Ontario (35%), practicing in academic centers (71%), with 45% reporting their practices focused primarily on genitourinary malignancies and one other tumor site. The majority were in practice 1 to 5 years (34%). Overall 65% indicated their practice patterns had changed since the pandemic, with 51% offering more ARATs and less docetaxel chemotherapy. In low volume mHSPC, the use of ARATs increased from 73% to 79%, while the use of docetaxel remained unaltered at 2%. In high volume disease, the use of ARATs increased from 63% to 84%, while the use of docetaxel decreased from 37% to 14%. Use of granulocyte colony stimulating factor (G-CSF) with docetaxel chemotherapy increased by 35%. Post-pandemic, 45% reported they intend to maintain these changes. Only 18% reported they had prostate cancer patients test positive for COVID-19, and all patients recovered.

CONCLUSION:

Management of patients with mHSPC in Canada has changed during the pandemic, with increased uptake of ARATs and reduced use of docetaxel, a trend expected to continue beyond the pandemic. How this trend will impact uptake of triplet therapy (ADT + ARAT + Docetaxel), downstream treatment choices and overall outcomes remains to be seen.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans / Male Country/Region as subject: North America Language: English Journal: Clin Genitourin Cancer Journal subject: Neoplasms / Urology Year: 2023 Document Type: Article Affiliation country: J.clgc.2022.11.020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans / Male Country/Region as subject: North America Language: English Journal: Clin Genitourin Cancer Journal subject: Neoplasms / Urology Year: 2023 Document Type: Article Affiliation country: J.clgc.2022.11.020